mar:val checks the target's technology, balance sheet and market position against registers, filed accounts and patent data, and tells you where the evidence runs out.
Name the company. mar:val finds it in the official register and follows its owners, hop by hop, until it reaches a natural person.
Target company
Novalis GmbH
In the register · GmbH · Munich · since 2014
Owners, hop by hop
Example · Novalis GmbH · Companies
Where its work sits among the field's categories, against the field as a whole, and how well each part of it is protected.
Share of familiesNovalisField
Protection · 24 families · Read as a moat
Example · Novalis GmbH · Technologies
A ranking from 0 to 100 with its five parts, and revenue growth set against growth in filings. Novalis grows fastest on both, but its revenue and its portfolio are small, so it ranks 61.
61of 100 · Mar:lean Ranking
Example · Novalis GmbH · Companies · Market
How strong its technology is, set against the resources its accounts show. Novalis has more technology than means: the gap your money, or a partner, would close.
Partner & out‑license
Example · Novalis GmbH · Technologies
Two methods value the technology, one from the market volume and one from the company's own revenue. How far they lie apart shows how firm the value is.
Technology value · 2 methods
$23–31M
Value per family · 24From revenueFrom the marketNo revenue
| Family | Role | Value | Valued from |
|---|---|---|---|
| 1 | Core | $2.3M | From revenue |
| 2 | Core | $1.9M | From revenue |
| 3 | Blocking | $1.3M | From revenue |
| 4 | Core | $2M | From revenue |
| 5 | Improvement | $0.9M | From revenue |
| 6 | Legacy | $0.2M | From the market |
| 7 | Core | $1.7M | From revenue |
| 8 | Improvement | $0.8M | From revenue |
| 9 | Core | $1.8M | From revenue |
| 10 | Blocking | $1.1M | From revenue |
| 11 | Defensive | $0.5M | From the market |
| 12 | Core | $1.5M | From revenue |
| 13 | Improvement | $0.8M | From revenue |
| 14 | Improvement | $1M | From the market |
| 15 | Core | $1.4M | From revenue |
| 16 | Improvement | $0.7M | From revenue |
| 17 | Defensive | $0.6M | From the market |
| 18 | Core | $1.4M | From revenue |
| 19 | Blocking | $1M | From revenue |
| 20 | Improvement | $0.7M | From revenue |
| 21 | Legacy | $0.3M | From the market |
| 22 | Core | $1.2M | From revenue |
| 23 | Defensive | $0.4M | From the market |
| 24 | Improvement | $0.5M | From revenue |
Example · Novalis GmbH · Technologies
Every round it received and every acquisition it made, each with date, amount, investors and its source. In the report, each source links to the reference.
ReceivedMade
| Date | Type | Amount | Investors · target | Source |
|---|---|---|---|---|
| 11 / 2024 | Received: Series B | $38M | Corvane Capital, Biosense AG | Press release |
| 09 / 2023 | Made: Acquisition | Undisclosed | Spectrane GmbH · calibration software | Register |
| 02 / 2021 | Received: Series A | $8M | Corvane Capital | Press release |
| 03 / 2019 | Received: Seed | $2.5M | Business angels | Register |
Example · Novalis GmbH · Investments
What is not on file is listed as missing. Missing evidence yields "not rated", never "low risk".
Example · Novalis GmbH · gaps as the report lists them
Each company shows which source a value came from and whether it was fetched fresh or served from cache. Legal statuses carry an as-of date and are flagged for re-verification after six months.
Then mar:val also sets its share price against five bases: earnings, revenue, book value, EBIT and dividend, with valuation bands. How far the five lie apart shows how firm the value is. For an unlisted target like Novalis, this comparison drops out, because it needs a share price.
No, and it doesn't claim to. The FTO module is a screen. It shows who could block you and where the search stops. Anything you act on should have been seen by your counsel.
Compare mode puts any number of targets side by side, one of them as the baseline, with deviations colour-marked across every metric group.
Demo request
In the demo we show you a real report from your technology field. 30 minutes, no obligation.
Questions first? contact@marlean.com